Collection 10 January 2024

Readers Choice: The best of Blood Cancer Journal 2023

In this collection we highlight a selection of articles from 2023, which top the list of the journal’s most cited, downloaded and most shared (including press coverage, blogs, Twitter, Facebook and Weibo). The articles showcase the breadth of scope and coverage that the journal consistently delivers to its readers.

Content

Management of chronic myeloid leukemia in 2023 – common ground and common sense
- Jayastu Senapati
- Koji Sasaki
- Hagop M. Kantarjian
Review ArticleOpen Access24 Apr 2023 Blood Cancer Journal
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
- José Luis Piñana
- Lourdes Vazquez
- Rodrigo Martino
ArticleOpen Access5 Jan 2023 Blood Cancer Journal
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
- Yinqiang Zhang
- Chenggong Li
- Heng Mei
ArticleOpen Access25 Apr 2023 Blood Cancer Journal
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
- Somayya Noori
- Charissa Wijnands
- Martijn M. van Duijn
CorrespondenceOpen Access24 Feb 2023 Blood Cancer Journal
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
- Hira Mian
- Arleigh McCurdy
- Tanya M. Wildes
ArticleOpen Access5 Jan 2023 Blood Cancer Journal
Global burden of hematologic malignancies and evolution patterns over the past 30 years
- Nan Zhang
- Jinxian Wu
- Fuling Zhou
ArticleOpen Access17 May 2023 Blood Cancer Journal
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
- Naseema Gangat
- Kebede H. Begna
- Ayalew Tefferi
ArticleOpen Access4 Jan 2023 Blood Cancer Journal
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
- Thomas Martin
- Meletios-Athanasios Dimopoulos
- Philippe Moreau
ArticleOpen Access9 May 2023 Blood Cancer Journal
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
- Rodrigo Fonseca
- Mariano Arribas
- Rafael Fonseca
ArticleOpen Access6 Mar 2023 Blood Cancer Journal
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
- Noopur Raje
- Kenneth Anderson
- Maria-Victoria Mateos
Review ArticleOpen Access1 Aug 2023 Blood Cancer Journal
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
- Christopher J. Ferreri
- Michelle A. T. Hildebrandt
- Omar Alexis Castaneda Puglianini
ArticleOpen Access9 Aug 2023 Blood Cancer Journal
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
- Beatrice Z. Sim
- Anthony Longhitano
- Benjamin W. Teh
CorrespondenceOpen Access10 Mar 2023 Blood Cancer Journal
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
- Xavier Cheng-Hong Tsai
- Kuo-Jui Sun
- Hwei-Fang Tien
ArticleOpen Access4 Jan 2023 Blood Cancer Journal
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
- Yuxuan Che
- Yang Liu
- Michael Wang
ArticleOpen Access17 Feb 2023 Blood Cancer Journal
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
- Marthe Minderman
- Hildo C. Lantermans
- Marcel Spaargaren
ArticleOpen Access15 Mar 2023 Blood Cancer Journal
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
- Elias K. Mai
- Stefanie Huhn
- Niels Weinhold
ArticleOpen Access4 Jan 2023 Blood Cancer Journal
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
- Utkarsh Goel
- Charalampos Charalampous
- Shaji K. Kumar
CorrespondenceOpen Access11 Jan 2023 Blood Cancer Journal
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
- Kelly von Beck
- Troy von Beck
- Ashwin Kishtagari
Review ArticleOpen Access4 Jan 2023 Blood Cancer Journal
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
- Jan-Niklas Eckardt
- Sebastian Stasik
- Christian Thiede
ArticleOpen Access24 Jan 2023 Blood Cancer Journal
Extreme body mass index and survival in newly diagnosed multiple myeloma patients
- Urvi A. Shah
- Karissa Whiting
- Ola Landgren
CorrespondenceOpen Access12 Jan 2023 Blood Cancer Journal
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
- Guadalupe Oñate
- Marta Pratcorona
- Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
ArticleOpen Access5 May 2023 Blood Cancer Journal
Multiple myeloma with acute light chain cast nephropathy
- Nelson Leung
- S. Vincent Rajkumar
Current Treatment AlgorithmOpen Access29 Mar 2023 Blood Cancer Journal
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
- Ayalew Tefferi
- Hassan Alkhateeb
- Naseema Gangat
Current Treatment AlgorithmOpen Access18 Jul 2023 Blood Cancer Journal
Zanubrutinib: past, present, and future
- Constantine S. Tam
- Javier L. Muñoz
- Stephen Opat
Review ArticleOpen Access11 Sep 2023 Blood Cancer Journal
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
- Rahul Banerjee
- Bo Wang
- Gurbakhash Kaur
CorrespondenceOpen Access6 Nov 2023 Blood Cancer Journal

Readers Choice: The best of Blood Cancer Journal 2023

Content

Management of chronic myeloid leukemia in 2023 – common ground and common sense

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review

Global burden of hematologic malignancies and evolution patterns over the past 30 years

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Multiple myeloma with acute light chain cast nephropathy

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm

Zanubrutinib: past, present, and future

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians

Search

Quick links